Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, on Tuesday reported financial results for the third quarter of 2023. Revenues
Gilead Sciences Inc.
-(GILD)
XLON:GILD
Gilead Sciences Q3 2023 Earnings: Stay tuned for the live earnings call and real-time transcript
Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, will be reporting third-quarter results today at 4:00 p.m. ET. Listen to
Gilead Sciences (GILD) Earnings: 2Q23 Key Numbers
Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.6 billion for the second quarter of 2023, which was up 5% year-over-year.
Gilead Sciences (GILD) Earnings: 1Q23 Key Numbers
Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.4 billion for the first quarter of 2023, which was down 4% year-over-year.
Infographic: Highlights of Gilead Sciences (GILD) Q4 2022 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) has reported a sharp increase in net profit for the fourth quarter of 2022 when
Infographic: Highlights of Gilead Sciences (GILD) Q3 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its third-quarter 2021 earnings today after the closing bell. The revenue increased by 13%
Gilead Sciences Inc (GILD) Q2 2021 Earnings Call Transcript
Gilead Sciences Inc (NASDAQ: GILD) Q2 2021 earnings call dated Jul. 29, 2021. Corporate Participants: Jacquie Ross -- Investor Relations Daniel O'Day --
Infographic: Highlights of Gilead Sciences (GILD) Q2 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its second-quarter 2021 earnings today after the closing bell. The revenue increased by 21%
Earnings calendar for the week of July 26
After showing weakness at the beginning of the week, benchmark stock indexes made steady gains even as economic recovery gathered steam. On
Infographic: Highlights of Gilead Sciences (GILD) Q1 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its first-quarter 2021 earnings today after the closing bell. The revenue increased by 16%
Earnings calendar for the week of April 26
Investor sentiment was hit by the government's proposal to levy higher capital gain tax on wealthy individuals, and the market shifted to
Earnings calendar for the week of February 1
In a week that saw one of the worst stock selloffs, Gamestop came under spotlight after the stock experienced unprecedented fluctuations, marked
Infographic: Highlights of Gilead Sciences (GILD) Q3 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) Wednesday said its third-quarter earnings increased, aided by higher revenues. The results also exceeded the
Gilead Sciences Inc. (GILD) Q2 2020 Earnings Call Transcript
Gilead Sciences Inc (NASDAQ: GILD) Q2 2020 earnings call dated July 30, 2020 Corporate Participants: Douglas Maffei -- Senior Director, Investor Relations Daniel O'Day -- Chairman
Infographic: Highlights from Gilead Sciences (GILD) Q2 2020 earnings
Gilead Sciences (NASDAQ: GILD) reported second-quarter financial results after the closing bell on Thursday. The biotechnology firm missed both the revenue and
Gilead Sciences Inc. (NASDAQ: GILD) Q1 2020 Earnings Call Transcript
Gilead Sciences Inc. (GILD) Q1 2020 earnings call dated April 30, 2020 Corporate Participants: Douglas Maffei -- Investor Relations Daniel O'Day -- Chairman and Chief Executive
Infographic: Highlights of Gilead Sciences (GILD) Q1 2020 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) Thursday said its first-quarter earnings increased, aided by higher revenues. The results also exceeded the
Gilead Sciences Inc (NASDAQ: GILD) Q4 2019 Earnings Call Transcript
Gilead Sciences Inc (NASDAQ: GILD) Q4 2019 Earnings Conference Call February 04, 2020 Corporate Participants: Douglas Maffei -- Investor Relations Daniel O'Day -- Chairman and Chief Executive
Companies that are working on the coronavirus vaccine
The coronavirus pandemic continues to plague the world with over 500,000 cases reported globally and over 82,000 cases in the US alone.
Gilead Sciences (GILD) stock falls as Q4 earnings miss estimates
Biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) reported a decline in fourth-quarter earnings, despite a modest increase in revenues. Earnings fell short
Gilead Sciences, Inc (GILD): Q3 2019 Earnings Snapshot
-- Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected. -- Total revenue remained